Cardiovascular and Metabolic Health

What we do

Cardiovascular and metabolic disease presents a tremendous, and increasing, health and economic burden for individuals and society worldwide. MIPS, home to more than 450 scientists, has a growing emphasis on multidiscipline cutting edge cardiometabolic research to address these global challenges.

MIPS expertise in Cardiovascular and Metabolic Health encompasses medicinal chemistry, structural biology, analytical pharmacology, drug disposition, drug delivery, translational models of disease and medicines use and safety. Our commitment to research translation is evidenced by contributing to more than 30 novel drug candidates into clinical development.

We have particular skills in:

the pharmacology of G protein-coupled receptors and the role of allostery and biased signalling in receptor pharmacology

structure-based drug design and the use of fragment-based screening in drug discovery

identification of optimal pharmaceutical properties for drug molecules during hit-to-lead and lead optimisation through to candidate selection

oral and pulmonary drug delivery and the use of nanomedicines in optimised drug therapy

cellular and animal physiology of cardiovascular and metabolic disease models

pharmacoepidemiology and pharmacometrics

Our focus

Cardiovascular research View

Metabolic research View

Program coordinators

Our highlights

Type 2 diabetes drug cost-effective for cardiovascular and kidney benefits, finds new study

The study, a collaboration between Monash University and the Baker Heart and Diabetes Institute, analysed the cardiovascular and kidney health benefits of SGLT2is - taking into account the economic costs for government.

MIPS researcher scores sought-after placement with CSL

Dr Sarah Turpin-Nolan is among 16 highly skilled researchers, clinicians and professionals to secure an industry placement under a coveted national fellowship program.

Genomics might be the key to primary prevention of cardiovascular disease

Australia’s healthcare resources are limited and, therefore, health interventions and therapeutics need to be shown to be cost-effective before governments and insurers will agree to provide them to, or subsidise them for, healthcare consumers.

New finding: nitroxyl represents a promising therapeutic intervention for cardiovascular emergencies in type 2 diabetes

A new study led by Monash University researchers has, for the first time, shown that the chemical compound 'nitroxyl' may represent an effective and rapid intervention for cardiovascular emergencies in type 2 diabetes.

The “master regulator” of inflammation: Monash researchers publish review on promising emerging drug target to treat chronic inflammatory states

Monash researchers, in collaboration with Queen Mary University of London, have published a state-of-the-art review on an emerging druggable target called FPR2, a key receptor involved in the regulation of inflammation.

Biotech start-up receives funding for anti-inflammatory research

A new start-up company led by researchers at The Australian National University and Monash University has received funding to develop a method to block inflammation caused by a number of common diseases, including cardiovascular disease,

New research into diabetes management in people who are frail

Monash University’s Centre for Medicine Use and Safety (CMUS) in collaboration with the Baker Heart and Diabetes Institute has released new research into the management of diabetes in people who are frail.

Monash University scientists review breadth of preclinical models of diabetic heart failure in pursuit of new treatments

A team of leading drug researchers have published a high impact review that sets out to provide guidance on how pre-clinical studies of diabetic heart failure should be designed to most closely mimic the human disease.

mRNA Victoria Research Acceleration Fund kickstarts project aimed at treating metabolic liver disease in infants and children

A team of MIPS mRNA researchers has partnered with the Children’s Medical Research Institute to combine mRNA delivery with viral gene delivery to treat metabolic liver disease in infants and children.

Monash Institute of Pharmaceutical Sciences

Monash Institute of Pharmaceutical Sciences

Cardiovascular and Metabolic Health